RetiVue
Private Company
Funding information not available
Overview
RetiVue is a private, commercial-stage diagnostics company specializing in accessible, high-definition ultrawidefield retinal imaging. Its core product line, the EntireEye suite, includes desktop and portable systems capable of capturing up to a 160° field of view in adults and 205° in babies, offering true-color, high-resolution images at a lower cost point than many traditional systems. The company is led by founder and CEO Paul Yates and appears to be in an early revenue-generating phase, selling its devices directly. Its primary market opportunity lies in expanding access to critical retinal diagnostics in both developed and underserved healthcare settings to enable earlier detection of diabetic retinopathy, retinopathy of prematurity, and other sight-threatening conditions.
Technology Platform
Ultrawidefield retinal imaging platform capable of capturing high-resolution, true-color fundus photos with a 160° field of view in adults and 205° in infants, designed for affordability and ease of use.
Opportunities
Risk Factors
Competitive Landscape
RetiVue competes in the retinal imaging market against large, established players like Nikon (Optos), Zeiss, and Centervue, which offer high-end widefield imaging systems at premium prices. Its primary competitive advantage is offering a compelling combination of widefield capability, image quality, and a significantly lower price point, targeting cost-conscious clinics and expanding access to underserved markets.